Chronic kidney disease prevalence in Rivas, Nicaragua: use of a field device for creatinine measurement
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Minnings, KaileyKerns, Eric
Fiore, Melissa
Fiore, Madeline
Parekh, Rulan S.
DuBois, Jeff
Isbell, T. Scott
Ferguson, Ryan
Fiore, Louis
Faculty Advisor
Ryan Ferguson (Boston University School of Public Health)Document Type
Journal ArticlePublication Date
2015-04-01Keywords
CreatinineFemale
Humans
Male
Nicaragua
Point-of-Care Systems
Prevalence
Renal Insufficiency, Chronic
Sensitivity and Specificity
Diagnosis
Female Urogenital Diseases and Pregnancy Complications
Male Urogenital Diseases
Medical Biochemistry
Nephrology
Metadata
Show full item recordAbstract
OBJECTIVE: An epidemic of chronic kidney disease (CKD) has been identified in Pacific coastal regions of Central America, and screening in the field in these low income countries remains logistically problematic. We tested the performance characteristics of a point of care creatinine analyzer compared to standardized serum creatinine measurements. METHODS: Measurements were conducted in 100 persons from a local health center (n=34) and hospital (n=66) in Rivas, Nicaragua using both a point-of-care analyzer (StatSensor Xpress, Nova Biomedical) and serum creatinine by Jaffe kinetic method with a Roche Cobas Integra 400 analyzer. Percent coefficient of variation, sensitivity and specificity of the StatSensor Xpress were determined. RESULTS: The average coefficient of variation (CV) was 1.28% for the serum creatinine and CV for the StatSensor Xpress analyzer was 6.8%. The median intra-individual creatinine results obtained with the StatSensor Xpress device were 0.32 mg/dL higher than those by serum creatinine by Jaffe kinetic method. The sensitivity and specificity of the StatSensor Xpress device for identifying subjects with abnormal creatinine (defined as > 1.2 mg/dL) was 100% and 79%, respectively. CONCLUSIONS: Point of care testing for creatinine demonstrated acceptable repeatability, excellent sensitivity (100%) and modest specificity (79%). Using the point of care testing will allow for generalized screening in the field in low income countries; however, confirmation for elevated levels > 1.2 mg/dL will require a second laboratory test confirmation.Source
Clin Biochem. 2015 Apr;48(6):456-8. doi: 10.1016/j.clinbiochem.2015.01.005. Epub 2015 Jan 21. Link to article on publisher's siteDOI
10.1016/j.clinbiochem.2015.01.005Permanent Link to this Item
http://hdl.handle.net/20.500.14038/49276PubMed ID
25617662Notes
Madeline Fiore participated in this study as a medical student as part of the Senior Scholars research program at the University of Massachusetts Medical School.
Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.clinbiochem.2015.01.005